Table 3.
LDL-C reduction under statins.
| APOE Variant | Pathogenic Prediction a | Gender | Age b | LDL-C without Preatment c | Treatment | Age d | LDL-C under Preatment c | Estimated Reduction e | Observed Reduction | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| rs776242156 | c.68C > T | p.Ala23Val | VUS/LP | M | 43 | 5.17 | Atorvastatin 20 | 46 | 1.42 | 1.8 | 3.6 |
| rs11542035 | c.410G > A | p.Arg137His | VUS/P | F | 61 | 6.45 | Simvastatin 20 | 62 | 3.06 | 1.6 | 2.1 |
| rs769455 | c.487C > T | p.Arg163Cys | VUS/P | M | 40 | 5.88 | Atorvastatin 80 Ezetimibe 10 | 41 | 1.69 | 2.5 | 3.5 |
| rs155726148 | c.500_502delTCC | p.Leu167del | LP | M | 69 | 7.24 | Atorvastatin 20 | 70 | 2.74 | 1.8 | 2.6 |
| rs155726148 | c.500_502delTCC | p.Leu167del | LP | F | 38 | 9.44 | Atorvastatin 80 | 56 | 3.59 | 2.2 | 2.6 |
| rs155726148 | c.500_502delTCC | p.Leu167del | LP | F | 31 | 6.18 | Atorvastatin 80 | 32 | 5.20 | 2.2 | 1.2 |
| rs155726148 | c.500_502delTCC | p.Leu167del | LP | M | 31 | 7.55 | Simvastatin 20 Ezetimibe 10 | 38 | 2.87 | 1.8 | 2.6 |
| rs155726148 | c.500_502delTTC | p.Leu167del | LP | M | 20 | 6.99 | Rosuvastatin 5 | 27 | 3.74 | 1.8 | 1.9 |
| rs781722239 | c.555C > T | p.Arg185= | LB | M | 65 | 7.81 | Atorvastatin 20 | 65 | 4.29 | 1.8 | 1.8 |
| rs267606661 | c.805C > G | p.Arg269Gly | VUS/P | M | 51 | 5.73 | Atorvastatin 20 | 58 | 3.18 | 1.8 | 1.8 |
| rs267606661 | c.805C > G | p.Arg269Gly | VUS/P | M | 59 | 6.33 | Atorvastatin 10 | 59 | 2.49 | 1.6 | 2.5 |
| Mean | 1.90 | 2.39 | |||||||||
| SD | 0.28 | 0.74 | |||||||||
| Wilcoxon matched-pairs test | p = 0.0426 | ||||||||||
a ACMG criteria from Varsome (Table 2); P: pathogenic; LP: likely pathogenic; VUS: variant of uncertain significance; LB: likely benign. b Age at lipid measurement without treatment. c mmol/L. d Age at lipid measurement under treatment. e Correction factors were obtained by the meta-analysis of 71 studies [34].